Annovis Bio, Inc. (ANVS)Healthcare | Biotechnology | Malvern, United States | NYSE
1.72 USD
-0.09
(-4.972%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 1.75 +0.03 (1.738%) ⇧ (Aug. 28, 2026, 7:54 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:12 a.m. EDT
The investment case for Annovis Bio is severely compromised by a deteriorating business trajectory and a lack of shareholder returns. Fundamentally, the company is trapped in a multi-year decline, having lost more than half its value over the last five years, with the last two years showing significant negative returns. This is compounded by negative earnings, negative book value, and a lack of any dividend history, leaving shareholders exposed to total capital erosion without income support. While analysts project a recovery to $11, the market has already priced in a catastrophic failure of the current business model, reflected in the stock trading near its 52-week lows. From a short-term perspective, the heavy put option positioning indicates that traders are betting on further weakness or high volatility, making any bounce a risky contrarian play. The combination of a sinking fundamental tide and aggressive bearish sentiment in the derivatives market suggests avoiding this security until there is clear evidence of a turnaround in clinical trials or revenue generation. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.051399 |
| AutoTheta | 0.051416 |
| MSTL | 0.053295 |
| AutoARIMA | 0.108295 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 1.30 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.252 |
| Excess Kurtosis | -0.72 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 73,282,584 |
| Forward P/E | -1.92 |
| Beta | 1.24 |
| Website | https://www.annovisbio.com |
As of Aug. 22, 2026, 5:12 a.m. EDT: Speculators are heavily positioned for downside protection, evidenced by massive open interest in out-of-the-money puts (strikes 0.5, 1.5, 2.0) relative to calls. While there is some speculative call volume at distant strikes (7.5, 17.5), the overwhelming capital allocation is in put writing and buying, suggesting a consensus expectation of continued volatility and potential further declines rather than a near-term rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.22317594 |
| Address1 | 101 Lindenwood Drive |
| Address2 | Suite 225 |
| All Time High | 132.0 |
| All Time Low | 1.11 |
| Ask | 1.82 |
| Ask Size | 6,800 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 573,170 |
| Average Daily Volume3 Month | 813,000 |
| Average Volume | 813,000 |
| Average Volume10Days | 573,170 |
| Beta | 1.24 |
| Bid | 1.72 |
| Bid Size | 2,200 |
| Book Value | -0.1 |
| City | Malvern |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.72 |
| Current Ratio | 3.466 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 1.83 |
| Day Low | 1.71 |
| Display Name | Annovis Bio |
| Earnings Timestamp End | 1,755,547,200 |
| Earnings Timestamp Start | 1,755,028,800 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 54,553,636 |
| Eps Current Year | -1.58 |
| Eps Forward | -0.895 |
| Eps Trailing Twelve Months | -1.66 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.7966 |
| Fifty Day Average Change | -0.076599956 |
| Fifty Day Average Change Percent | -0.042636067 |
| Fifty Two Week Change Percent | -22.317595 |
| Fifty Two Week High | 5.5 |
| Fifty Two Week High Change | -3.78 |
| Fifty Two Week High Change Percent | -0.6872727 |
| Fifty Two Week Low | 1.54 |
| Fifty Two Week Low Change | 0.18000007 |
| Fifty Two Week Low Change Percent | 0.116883166 |
| Fifty Two Week Range | 1.54 - 5.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,580,308,200,000 |
| Float Shares | 35,319,648 |
| Forward Eps | -0.895 |
| Forward P E | -1.9217877 |
| Free Cashflow | -23,794,514 |
| Full Exchange Name | NYSE |
| Full Time Employees | 7 |
| Fullday Change | -0.0899999 |
| Fullday Change Percent | -4.97237 |
| Fullday Price | 1.7499 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06713 |
| Held Percent Institutions | 0.27907 |
| Implied Shares Outstanding | 42,606,152 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania. |
| Long Name | Annovis Bio, Inc. |
| Market | us_market |
| Market Cap | 73,282,584 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_622711087 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -49,524,268 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 77,117,135 |
| Number Of Analyst Opinions | 3 |
| Open | 1.78 |
| Operating Cashflow | -43,339,896 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 484 875 3192 |
| Post Market Change | 0.029899955 |
| Post Market Change Percent | 1.7383695 |
| Post Market Price | 1.7499 |
| Post Market Time | 1,787,961,285 |
| Previous Close | 1.81 |
| Price Eps Current Year | -1.0886075 |
| Price Hint | 4 |
| Price To Book | -17.2 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.945 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | -0.0899999 |
| Regular Market Change Percent | -4.97237 |
| Regular Market Day High | 1.83 |
| Regular Market Day Low | 1.71 |
| Regular Market Day Range | 1.71 - 1.83 |
| Regular Market Open | 1.78 |
| Regular Market Previous Close | 1.81 |
| Regular Market Price | 1.72 |
| Regular Market Time | 1,787,947,202 |
| Regular Market Volume | 498,121 |
| Return On Assets | -1.42358 |
| Return On Equity | -7.03678 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 42,606,152 |
| Shares Percent Shares Out | 0.1165 |
| Shares Short | 4,964,649 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 5,450,385 |
| Short Name | Annovis Bio, Inc. |
| Short Percent Of Float | 0.1279 |
| Short Ratio | 8.09 |
| Source Interval | 15 |
| State | PA |
| Symbol | ANVS |
| Target High Price | 17.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 11.0 |
| Target Median Price | 8.0 |
| Total Cash | 18,728,944 |
| Total Cash Per Share | 0.44 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.66 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.48465 |
| Two Hundred Day Average Change | -0.76464987 |
| Two Hundred Day Average Change Percent | -0.30774954 |
| Type Disp | Equity |
| Volume | 498,121 |
| Website | https://www.annovisbio.com |
| Zip | 19,355 |